Insight Molecular Diagnostics (IMDX) Operating Margin (2020 - 2026)
Insight Molecular Diagnostics (IMDX) posted Operating Margin of 13790.62% for Q1 2026, down 1016.32% sequentially from 1505.0% in Q4 2025, and down 1347262.0% YoY from N/an in Q1 2025.
Insight Molecular Diagnostics (IMDX) Operating Margin (2020 - 2026) Analysis & Trends
Insight Molecular Diagnostics (IMDX) has 7 years of Operating Margin data on file, last reported at 13790.62% in Q1 2026.
- Quarterly Operating Margin fell 1347262.0% year-over-year to 13790.62% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 418.73% (down 15146.0% YoY) and the FY2025 annual result came in at 260.1%, up 41715.0% from the prior year.
- Operating Margin eased to 13790.62% in Q1 2026 per IMDX's latest filing, from 1505.0% in the prior quarter.
- The five-year high for Operating Margin was 1969.7% in Q1 2023, with the low at 13790.62% in Q1 2026.
- Average Operating Margin over 5 years is 3176.85%, with a median of 1900.0% recorded in 2025.
- Year-over-year, Operating Margin surged 750294 bps in 2025 and tumbled 1347262 bps in 2026.
- Insight Molecular Diagnostics' Operating Margin stood at 4251.09% in 2022, then declined by 21 bps to 5152.55% in 2023, then jumped by 119 bps to 987.55% in 2024, then surged by 52 bps to 1505.0% in 2025, then plunged by 1016 bps to 13790.62% in 2026.
- Business Quant data shows IMDX's Operating Margin at 13790.62% in Q1 2026, 1505.0% in Q4 2025, and 4249.23% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 31,055.11 Bn | 31,054.65 Bn | 1.11 Bn | -3.71% |
| 2 | Thermo Fisher Scientific | 191.02 Bn | 187.77 Bn | 7.74 Bn | 16.93% |
| 3 | Danaher | 137.16 Bn | 131.47 Bn | 3.59 Bn | 22.58% |
| 4 | Idexx Laboratories | 42.82 Bn | 42.62 Bn | 722.74 Mn | 31.78% |
| 5 | Natera | 39.09 Bn | 37.99 Bn | 696.04 Mn | -13.42% |
| 6 | Agilent Technologies | 37.61 Bn | 35.81 Bn | 990.00 Mn | 21.74% |
| 7 | Iqvia Holdings | 34.23 Bn | 32.25 Bn | 1.36 Bn | 12.38% |
| 8 | Illumina | 28.14 Bn | 26.98 Bn | 721.00 Mn | 19.16% |
| 9 | Mettler Toledo International | 26.40 Bn | 26.33 Bn | 555.82 Mn | 25.23% |
| 10 | Insight Molecular Diagnostics | 196.41 Mn | 167.48 Mn | 15,000.00 | -13,790.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13,790.63% |
| Dec 31, 2025 | 1,505.00% |
| Sep 30, 2025 | -4,249.23% |
| Jun 30, 2025 | -1,900.00% |
| Mar 31, 2025 | -318.01% |
| Dec 31, 2024 | 987.55% |
| Sep 30, 2024 | -11,752.17% |
| Jun 30, 2024 | -4,453.85% |
| Mar 31, 2024 | -5,265.34% |
| Dec 31, 2023 | -5,152.55% |
| Sep 30, 2023 | -1,518.18% |
| Jun 30, 2023 | -1,791.36% |
| Mar 31, 2023 | 1,969.70% |
| Dec 31, 2022 | -4,251.09% |
| Sep 30, 2022 | -2,546.27% |
| Jun 30, 2022 | -686.08% |
| Mar 31, 2022 | -793.95% |
| Dec 31, 2021 | -994.15% |
| Sep 30, 2021 | -1,382.52% |
| Jun 30, 2021 | -668.37% |